CRUCELL AND US NAVY SIGN AGREEMENT TO TEST ADVAC-BASED VACCINE AGAINST ANTHRAX AND PLAGUE

Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has signed a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Center of the US Navy to construct AdVac(R)-based vaccines against anthrax and plague and test them in non-human primates. Like Ebola and Marburg, anthrax and plague are among the so-called 'Category A' agents, which are considered by the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) to pose a significant risk in the event of use as bioterrorist agents.

PrimeZone (http://www.primezone.com/newsroom/news.html?d=84097)